UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

PMD85 Sleep Questionnaires Discriminate Between Participants With and Without Overactive Bladder Symptoms

Value in health, 2011, Vol.14 (7), p.A259-A260

2011

Volltextzugriff (PDF)

Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder

The American journal of managed care, 2005-07, Vol.11 (4 Suppl), p.S140-S149

2005

Volltextzugriff (PDF)

Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine

International journal of clinical practice (Esher), 2008-06, Vol.62 (6), p.925-931

2008

Volltextzugriff (PDF)

Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin

The American journal of managed care, 2005-07, Vol.11 (4 Suppl), p.S150-S157

2005

Volltextzugriff (PDF)

Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates

The American journal of managed care, 2005-07, Vol.11 (4 Suppl), p.S130-S139

2005

Volltextzugriff (PDF)

Persistence with overactive bladder pharmacotherapy in a Medicaid population

The American journal of managed care, 2005-07, Vol.11 (4 Suppl), p.S121-S129

2005

Volltextzugriff (PDF)

OP284. 難治性肺MAC症に対する吸入用アミカシンリポソーム懸濁液 (ALIS) - CONVERT試験日本人サブ解析

日本呼吸器学会誌, 2021-04, Vol.10 (suppl), p.185-185

2021

Volltextzugriff (PDF)

The Validation of Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue—The BSW

Value in health, 2005-11, Vol.8, p.S25-S34

2005

Volltextzugriff (PDF)

Urinary incontinence in the nursing home: resident characteristics and prevalence of drug treatment

The American journal of managed care, 2005-07, Vol.11 (4 Suppl), p.S112-S120

2005

Volltextzugriff (PDF)

Meeting the obligation to communicate clinical trial results to study volunteers

Expert review of clinical pharmacology, 2012-03, Vol.5 (2), p.149-156

2012

Volltextzugriff (PDF)

274 EFFECT OF A MODERATE CYP3A4 INHIBITOR, FLUCONAZOLE, ON THE PHARMACOKINETICS OF FESOTERODINE IN HEALTHY SUBJECTS

European urology supplements : official journal of the European Association of Urology, 2010-04, Vol.9 (2), p.113-114

2010

Volltextzugriff (PDF)

Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin

American journal of health-system pharmacy, 2006-12, Vol.63 (23), p.2357-2364

2006

Volltextzugriff (PDF)

PUK18 VALIDATION OF THE URINARY SENSATION SCALE (USS)

Value in health, 2008, Vol.11 (6), p.A655-A655

2008

Volltextzugriff (PDF)

Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine: Related improvements in OAB symptoms and PROs

International journal of clinical practice (Esher), 2008-06, Vol.62 (6), p.925-931

2008

Volltextzugriff (PDF)

PUK6 ECONOMIC IMPACT OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PERSONS WITH OVERACTIVE BLADDER

Value in health, 2005-11, Vol.8 (6), p.A79-A79

2005

Volltextzugriff (PDF)

PUK3 AN ECONOMIC MODEL OF OVERACTIVE BLADDER TREATMENT PERSISTENCE:TOLTERODINE ER COMPARED TO OXYBUTYNIN ER

Value in health, 2005-05, Vol.8 (3), p.413-414

2005

Volltextzugriff (PDF)

CS3 IMPACT OF ESTIMATION TECHNIQUE ON MEDICAL COST ESTIMATES FOR OVERACTIVE BLADDER TREATMENTS

Value in health, 2005-05, Vol.8 (3), p.249-249

2005

Volltextzugriff (PDF)

CS7 OVERCOMING SAMPLE-SELECTION CHALLENGES IN ECONOMIC COMPARISONS OF DRUG AND NON-DRUG THERAPY: THE CASE OF OVERACTIVE BLADDER

Value in health, 2005-05, Vol.8 (3), p.254-254

2005

Volltextzugriff (PDF)

PUK11 ADHERENCE TO EXTENDED RELEASE TOLTERODINE VERSUS IMMEDIATE- AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PATIENTS WITH OVERACTIVE BLADDER

Value in health, 2005-05, Vol.8 (3), p.416-416

2005

Volltextzugriff (PDF)

PUK20 IMPLICATIONS OF OVERACTIVE BLADDER ICD-9 CODE CHANGES AND USE OF CODES IN A MANAGED CARE POPULATION

Value in health, 2004-11, Vol.7 (6), p.804-804

2004

Volltextzugriff (PDF)

PUK3 ECONOMIC IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY-INSURED PERSONS ≥65 YEARS OF AGE WITH OVERACTIVE BLADDER

Value in health, 2006-05, Vol.9 (3), p.A95-A96

2006

Volltextzugriff (PDF)

HI2 CLINICAL IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY INSURED PERSONS AGED ≥65 YEARS WITH OVERACTIVE BLADDER

Value in health, 2006-05, Vol.9 (3), p.A14-A14

2006

Volltextzugriff (PDF)

QL1 DETERMINING THE MINIMALLY IMPORTANT DIFFERENCE OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q)

Value in health, 2005-11, Vol.8 (6), p.A9-A9

2005

Volltextzugriff (PDF)

PUK19 ESTABLISHING THE CONTENT VALIDITY OF THE URINARY SENSATION SCALE (USS)

Value in health, 2005-05, Vol.8 (3), p.418-419

2005

Volltextzugriff (PDF)

PUK20 PATIENT SELECTION CRITERIA IMPACTS OUTCOMES IN A RETROSPECTIVE OAB STUDY

Value in health, 2005-05, Vol.8 (3), p.419-419

2005

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(29)

Sprache

Englisch
(28)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PMD85 Sleep Questionnaires Discriminate Between Participants With and Without Overactive Bladder Symptoms

Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder

Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine

Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin

Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates

Persistence with overactive bladder pharmacotherapy in a Medicaid population

OP284. 難治性肺MAC症に対する吸入用アミカシンリポソーム懸濁液 (ALIS) - CONVERT試験日本人サブ解析

The Validation of Patient-Rated Global Assessments of Treatment Benefit, Satisfaction, and Willingness to Continue—The BSW

Urinary incontinence in the nursing home: resident characteristics and prevalence of drug treatment

Meeting the obligation to communicate clinical trial results to study volunteers

274 EFFECT OF A MODERATE CYP3A4 INHIBITOR, FLUCONAZOLE, ON THE PHARMACOKINETICS OF FESOTERODINE IN HEALTHY SUBJECTS

Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin

PUK18 VALIDATION OF THE URINARY SENSATION SCALE (USS)

Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine: Related improvements in OAB symptoms and PROs

PUK6 ECONOMIC IMPACT OF EXTENDED-RELEASE TOLTERODINE VERSUS IMMEDIATE-AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PERSONS WITH OVERACTIVE BLADDER

PUK3 AN ECONOMIC MODEL OF OVERACTIVE BLADDER TREATMENT PERSISTENCE:TOLTERODINE ER COMPARED TO OXYBUTYNIN ER

CS3 IMPACT OF ESTIMATION TECHNIQUE ON MEDICAL COST ESTIMATES FOR OVERACTIVE BLADDER TREATMENTS

CS7 OVERCOMING SAMPLE-SELECTION CHALLENGES IN ECONOMIC COMPARISONS OF DRUG AND NON-DRUG THERAPY: THE CASE OF OVERACTIVE BLADDER

PUK11 ADHERENCE TO EXTENDED RELEASE TOLTERODINE VERSUS IMMEDIATE- AND EXTENDED-RELEASE OXYBUTYNIN AMONG COMMERCIALLY-INSURED PATIENTS WITH OVERACTIVE BLADDER

PUK20 IMPLICATIONS OF OVERACTIVE BLADDER ICD-9 CODE CHANGES AND USE OF CODES IN A MANAGED CARE POPULATION

PUK3 ECONOMIC IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY-INSURED PERSONS ≥65 YEARS OF AGE WITH OVERACTIVE BLADDER

HI2 CLINICAL IMPACT OF PHARMACOTHERAPYVERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY INSURED PERSONS AGED ≥65 YEARS WITH OVERACTIVE BLADDER

QL1 DETERMINING THE MINIMALLY IMPORTANT DIFFERENCE OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q)

PUK19 ESTABLISHING THE CONTENT VALIDITY OF THE URINARY SENSATION SCALE (USS)

PUK20 PATIENT SELECTION CRITERIA IMPACTS OUTCOMES IN A RETROSPECTIVE OAB STUDY

Suchergebnisse filtern